Adjuvanticity of pGPL-Mc and LRS in the immune responses of monkeys to oral immunization with diphtheria and tetanus toxoids

Mirchamsy, H.; Neway, T.; Hamedi, Mohammad; Pilet, Charles

doi:10.1016/s0147-9571(96)00030-6

Cited by 2 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Widespread vaccine production and administration during this period was followed by a 99% decrease in reported measles cases, resulting in large economic savings (Figures 1 and 2). In the pre-vaccine era, measles was a common infectious disease with high incidence, morbidity and mortality (29).…”

Section: Comparative Epidemiology Of Measles; Pre-and Postvaccine Eramentioning

confidence: 99%

See 1 more Smart Citation

Measles Vaccines in Iran: A 50-Year Review of Vaccine Development, Production and Effectiveness (1967 - 2017)

Shafyi

Mohammadi

2018

Jundishapur J Microbiol

View full text Add to dashboard Cite

Context: Information on the measles vaccine is important for future measles control policies. Vaccination history and laboratory confirmation during the development of the AIK measles vaccine in Iran is surveyed in this article. In addition, the production results and effectiveness of the Razi AIK-C/MRC-5 measles strain are compared with other vaccine strains.Evidence Acquisition: The current study was carried out to aim local measles vaccine manufacturing and consequences of that in Iran, using various search engines. Almost complete search carried out in medical databases including PubMed, Scopus, Web of Science, Scientific Information Database, IranMedex, Magiran and Google Scholar. Results: The morbidity rate of measles during the pre-vaccine era of this disease was 10,000 cases/year in 1970 -1972. In 1997, the rate was 24 in 1000 cases. After using the high quality Razi measles vaccine between 1995 and 2013, the number of measles-positive cases declined to a maximum of 35 cases per year, while the country's population increased by more than 2.5 times. The median of the Razi measles vaccine efficacy (VE) was > 92.1% compared with that of the pre-vaccine era. For patients who received 2 doses of the measles vaccine at either 6 and 12 months or 9 and 18 months of age, the median VEs were > 90.0% (interquartile range [IQR], 83% -97%) and 92.0% (IQR, 86% -98%), respectively. The age at vaccination and strain type used in the vaccines are reviewed in this article. Conclusion:The effectiveness of the local Razi measles vaccine resulted in a significant decline in measles mortality and morbidity in Iran. Two doses of the Razi measles (MR) or measles combination (MMR) vaccine provided excellent protection against measles. The seroprevalance of the measles vaccine in Iran revealed that more than 90% of Iranians are seropositive for the measles virus.

show abstract

Section: Comparative Epidemiology Of Measles; Pre-and Postvaccine Eramentioning

confidence: 99%

“…This means that for 1 death in the USA, there were 17 measles-related deaths in India. At the same time in Africa, Asia and Latin America there were 50 deaths per 100,000 residents (29). Immunization against measles in Iran started in 1967 with a population of 30 million.…”

Section: Comparative Epidemiology Of Measles; Pre-and Postvaccine Eramentioning

confidence: 99%

Measles Vaccines in Iran: A 50-Year Review of Vaccine Development, Production and Effectiveness (1967 - 2017)

Shafyi

Mohammadi

2018

Jundishapur J Microbiol

View full text Add to dashboard Cite

show abstract

“…Thus, many adjuvants or protective carrier vehicles have been tested. Nowadays, those certified are mostly composed of polymers, liposomes, aluminium hydroxide as well as synthetic mesoporous silica (Mirchamsy et al, 1997;Caldero ´n & Sosnik, 2015;Mercuri et al, 2006;Vallhov et al, 2007). The improvement triggered by silica on the immunological responsiveness has been known since 1987 (Gennari et al, 1987).…”

Section: Introductionmentioning

confidence: 99%

Using crystallography tools to improve vaccine formulations

Fantini

Oliveira

Lopes

et al. 2021

Int Union Crystallogr J

View full text Add to dashboard Cite

This article summarizes developments attained in oral vaccine formulations based on the encapsulation of antigen proteins inside porous silica matrices. These vaccine vehicles show great efficacy in protecting the proteins from the harsh acidic stomach medium, allowing the Peyer's patches in the small intestine to be reached and consequently enhancing immunity. Focusing on the pioneering research conducted at the Butantan Institute in Brazil, the optimization of the antigen encapsulation yield is reported, as well as their distribution inside the meso- and macroporous network of the porous silica. As the development of vaccines requires proper inclusion of antigens in the antibody cells, X-ray crystallography is one of the most commonly used techniques to unveil the structure of antibody-combining sites with protein antigens. Thus structural characterization and modelling of pure antigen structures, showing different dimensions, as well as their complexes, such as silica with encapsulated hepatitis B virus-like particles and diphtheria anatoxin, were performed using small-angle X-ray scattering, X-ray absorption spectroscopy, X-ray phase contrast tomography, and neutron and X-ray imaging. By combining crystallography with dynamic light scattering and transmission electron microscopy, a clearer picture of the proposed vaccine complexes is shown. Additionally, the stability of the immunogenic complex at different pH values and temperatures was checked and the efficacy of the proposed oral immunogenic complex was demonstrated. The latter was obtained by comparing the antibodies in mice with variable high and low antibody responses.

show abstract

Adjuvanticity of pGPL-Mc and LRS in the immune responses of monkeys to oral immunization with diphtheria and tetanus toxoids

Cited by 2 publications

References 14 publications

Measles Vaccines in Iran: A 50-Year Review of Vaccine Development, Production and Effectiveness (1967 - 2017)

Measles Vaccines in Iran: A 50-Year Review of Vaccine Development, Production and Effectiveness (1967 - 2017)

Using crystallography tools to improve vaccine formulations

Contact Info

Product

Resources

About